Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06256237
Other study ID # LungMate-023
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date April 1, 2024
Est. completion date January 31, 2032

Study information

Verified date May 2024
Source Shanghai Pulmonary Hospital, Shanghai, China
Contact Peng Zhang, PhD
Phone 02165115006
Email zhangpeng1121@tongji.edu.cn
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

For limited-stage small cell lung cancer (SCLC), neoadjuvant chemotherapy plus PD-1 antibody is recommended. However, most patients cannot achieve a complete pathological response (CPR). A new immunotherapeutic strategy is needed to achieve a higher CPR rate. JS004 is a new antibody targeting B and T lymphocyte attenuator (BTLA), which restrains immune cells' function and leads to immune escape of tumor cells. The combination of PD-1 and BTLA antibodies has shown a good therapeutic effect in solid tumors. This trial aims to investigate the efficacy and safety of the therapeutic regimen of toripalimab and JS004 plus etoposide and platinum Chemotherapy in limited-stage SCLC.


Recruitment information / eligibility

Status Recruiting
Enrollment 30
Est. completion date January 31, 2032
Est. primary completion date January 31, 2027
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. The patient shall sign the Informed Consent Form. 2. Aged 18 = years. 3. Histological or cytological diagnosis of SCLC by needle biopsy, and limited stage confirmed by imageological examinations (CT, PET-CT or EBUS). 4. Eastern Cooperative Oncology Group (ECOG) performance-status score of 0 or 1. 5. Life expectancy is at least 12 weeks. 6. At least 1 measurable lesion according to RECIST 1.1. 7. Patients with good function of other main organs (liver, kidney, blood system, etc.) 8. Without systematic metastasis (including M1a, M1b and M1c); 9. Expected to be completely resected 10. Patients with lung function can tolerate surgery 11. Fertile female patients must voluntarily use effective contraceptives not less than 120 days after chemotherapy or the last dose of toripalimab (whichever is later) during the study period, and urine or serum pregnancy test results within 7 days prior to enrollment are negative. 12. Unsterilized male patients must voluntarily use effective contraception during the study period not less than 120 days after chemotherapy or the last dose of toripalimab (whichever is later). Exclusion Criteria: 1. Participants who have received any systemic anti-cancer treatment for thymic epithelial tumor, including surgical treatment, local radiotherapy, cytotoxic drug treatment, targeted drug treatment and experimental treatment; 2. Patients with a malignancy other than SCLC within five years prior to the start of this trial; 3. Participants with any unstable systemic disease (including active infection, uncontrolled hypertension), unstable angina pectoris, angina pectoris starting in the last three months, congestive heart failure (>= NYHA) Grade II), myocardial infarction (6 months before admission), severe arrhythmia requiring drug treatment, liver, kidney or metabolic diseases; 4. With activate or suspectable autoimmune disease, or autoimmune paracancer syndrome requiring systemic treatment; 5. Participants who are allergic to the test drug or any auxiliary materials; 6. Participants with Interstitial lung disease currently; 7. Participants with active hepatitis B, hepatitis C or HIV; 8. Pregnant or lactating women; 9. Any malabsorption; 10. Participants suffering from nervous system diseases or mental diseases that cannot cooperate 11. Other factors that researchers think it is not suitable for enrollment.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
JS004
Specified dose on specified days.
Toripalimab
Specified dose on specified days.
Procedure:
surgery
Patients with resectable tumors after neoadjuvant therapy will be treated with surgery.
Drug:
Etoposide
Specified dose on specified days.
Platinum
Specified dose on specified days.

Locations

Country Name City State
China Shanghai Pulmonary Hospital Shanghai

Sponsors (1)

Lead Sponsor Collaborator
Shanghai Pulmonary Hospital, Shanghai, China

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Pathologic complete response (PCR) rate PCR rate is defined as the proportion of participants who have achieved pathologic complete response (on routine hematoxylin and eosin staining, no tumor cell can be found in tumor bed or lymph node) in all participants. Up to 30 months
Secondary Objective response rate (ORR) ORR is defined according to the RECIST v1.1 criteria. up to 30 months
Secondary Major pathologic response (MPR) rate MPR rate is defined as the proportion of participants who have achieved major pathologic response (on routine hematoxylin and eosin staining, tumors with no more than 10% viable tumor cells) in all participants. Up to 30 months
Secondary Treatment-related adverse event (TRAE) TRAE is defined and classified according to NCI-CTCAE v5.0 in all participants. Up to 30 months
Secondary Event-free survival (EFS) Event-free survival (EFS) is defined as the length of time (months) from randomization to any of the following events: any progression of disease precluding surgery, progression or recurrence disease based on response evaluation criteria in solid tumors (RECIST) 1.1 after surgery, or death due to any cause. Participants who don't undergo surgery for reason other than progression will be considered to have an event at progression or death. Progression is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression). up to 60 months
Secondary Overall survival (OS) It is defined as the time (months) from enrollment to death of participant due to any cause. In the case of a patient who still survives at the time of analysis, the date of last contact will be taken as the censoring date. up to 60 months
Secondary EORTC-QLQ-C30 scale The assessment is made according to the Quality of Life Scale for Lung Cancer Patients (EORTC-QLQ-C30, Version 3). EORTC's QLQ-C30 (V3.0) is a core scale for lung cancer patients, with a total of 30 items. Among them, Item 29 and 30 are divided into seven grades, which are assigned with 1 to 7 scores according to the answer options. The other items are divided into 4 grades: Not at All, A Little, Quite a Bit, and Very Much, assigned with 1 to 4 scores respectively. The higher score, the worse quality. up to 5 months
See also
  Status Clinical Trial Phase
Completed NCT01935336 - Study of Ponatinib in Patients With Lung Cancer Preselected Using Different Candidate Predictive Biomarkers Phase 2
Recruiting NCT05443646 - Consolidation Serplulimab Following Concurrent Chemoradiotherapy for LS-SCLC Patients Phase 2
Completed NCT00066742 - Tirapazamine Combined With Chemo and RT in Limited-Stage Small Cell Lung Cancer Phase 2
Recruiting NCT05034133 - Durvalumab With Chemotherapy Followed by Sequential Radiotherapy for Limited Stage Small Cell Lung Cancer Phase 2
Recruiting NCT04790253 - PRophylactic Cerebral Irradiation or Active MAgnetic Resonance Imaging Surveillance in Small-cell Lung Cancer Patients (PRIMALung Study) N/A
Recruiting NCT05942508 - A Phase Ib Study of TQB2450 Combined With Anlotinib in Patients With Limited Stage Small Cell Lung Cancer After First-line Radiotherapy and Chemotherapy Phase 1
Completed NCT00019006 - Vaccine Therapy in Treating Patients With Colon, Pancreatic, or Lung Cancer Phase 1
Recruiting NCT05483543 - Pamiparib for Consolidation Treatment of Unprogressed LS-SCLC After Concurrent Chemoradiotherapy Phase 2
Active, not recruiting NCT02046733 - Small Cell Lung Carcinoma Trial With Nivolumab and IpiliMUmab in LImited Disease Phase 2
Completed NCT04952597 - Study of Ociperlimab Plus Tislelizumab Plus Chemoradiotherapy in Participants With Untreated Limited-Stage Small Cell Lung Cancer Phase 2
Recruiting NCT05623267 - Sugemalimab as Consolidation Therapy in Patients With LS-SCLC Following cCRT or sCRT Phase 2/Phase 3
Completed NCT01457469 - Enhanced Quitline Intervention in Smoking Cessation for Patients With Non-Metastatic Lung Cancer Phase 1
Recruiting NCT06117774 - Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC) Phase 3
Completed NCT01999881 - Impacts of Exercise on Prognostic Biomarkers in Lung Cancer Patients N/A
Not yet recruiting NCT05496166 - The Efficiency of Surgery and Radiotherapy After SHR-1316 (Adebrelimab) and Platinum-containing Doublet Induction Therapy for Limited-stage Small Cell Lung Cancer Phase 3
Recruiting NCT04829708 - Efficacy and Safety of Prophylactic Cranial Irradiation Versus MRI Surveillance in Patients With Limited-stage Small Cell Lung Cancer Who Achieved Remission After First-line Chemoradiotherapy Phase 3
Completed NCT00470054 - Dasatinib in Treating Patients With Relapsed Small Cell Lung Cancer Phase 2
Terminated NCT00084487 - Rebeccamycin Analog as Second-Line Therapy in Treating Patients With Limited-Stage or Extensive-Stage Small Cell Lung Cancer That Relapsed After Previous First-Line Chemotherapy Phase 2